ArticleVirology journal2025
Immunogenicity of a foot-and-mouth disease (FMD) vaccine against serotypes O, A, SAT-2, and Asia-1 in the Middle East and many parts of Africa, Southeast Asia and Europe.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Protective Effect ofMicroorganisms · 2026Article
- Lumpy Skin Disease Virus (LSDV) recently emerged in Egypt: molecular detection, and assessment of the related hematobiochemical, and risk factors.BMC veterinary research · 2026Article
- Seroprevalence and risk factors associated with calves' cryptosporidiosis in Egypt.BMC veterinary research · 2026Article
- Concurrent administration of a combined clostridial vaccine or ivermectin suppresses the antibody response to foot-and-mouth disease vaccine in sheep.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Control of foot-and-mouth disease (FMD) is hampered by inadequate biosecurity measures, border transcending serotype strains and unavailability of broad coverage vaccines. In this investigation, six FMD antibody-free calves, aged 1.5-2 years, received a tetravalent, inactivated, aluminum hydroxide gel vaccine (Aphthovac-4) containing 6 PD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.